ReviewCancer innovation2026
Molecular and Genetic Landscape of Intravenous Leiomyomatosis: A Narrative Review.
Review in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular and Genetic Landscape of Intravenous Leiomyomatosis: A Narrative Review.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravenous leiomyomatosis (IVL) is a rare benign smooth muscle tumor originating from the uterus and characterized by intravascular growth along the venous system, with potential extension to the inferior vena cava, right heart, or pulmonary arteries, leading to life-threatening cardiorespiratory complications. IVL carries a 10%-31% recurrence rate and exhibits quasimalignant biological behavior despite its benign histology. Surgical resection is the main treatment. Current studies on IVL remain limited with regard to molecular and genetic mechanisms. This review systematically summarizes the research progress on IVL from the perspectives of chromosomal aberrations, copy number variations, gene mutations, transcriptomics, proteomics, histopathology, and epigenetic alterations. In addition, IVL is compared with uterine leiomyoma, leiomyosarcoma, and benign metastasizing leiomyoma to clarify its similarities and differences. This review also discusses unresolved issues, including tumor origin, intravascular invasive mechanisms and recurrence biomarkers, as well as prospects for future directions. A comprehensive understanding of the genetic and molecular features of IVL will help elucidate its pathogenesis, improve differential diagnosis and clinical management, and provide a theoretical basis for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.